JP2021503490A5 - - Google Patents

Download PDF

Info

Publication number
JP2021503490A5
JP2021503490A5 JP2020543658A JP2020543658A JP2021503490A5 JP 2021503490 A5 JP2021503490 A5 JP 2021503490A5 JP 2020543658 A JP2020543658 A JP 2020543658A JP 2020543658 A JP2020543658 A JP 2020543658A JP 2021503490 A5 JP2021503490 A5 JP 2021503490A5
Authority
JP
Japan
Prior art keywords
compound according
compound
formula
derivative
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020543658A
Other languages
English (en)
Japanese (ja)
Other versions
JP7282792B2 (ja
JP2021503490A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2018/051336 external-priority patent/WO2019075583A1/en
Publication of JP2021503490A publication Critical patent/JP2021503490A/ja
Publication of JP2021503490A5 publication Critical patent/JP2021503490A5/ja
Priority to JP2023081323A priority Critical patent/JP7592120B2/ja
Application granted granted Critical
Publication of JP7282792B2 publication Critical patent/JP7282792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543658A 2017-10-22 2018-10-22 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物 Active JP7282792B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023081323A JP7592120B2 (ja) 2017-10-22 2023-05-17 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762575460P 2017-10-22 2017-10-22
US62/575,460 2017-10-22
PCT/CA2018/051336 WO2019075583A1 (en) 2017-10-22 2018-10-22 NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023081323A Division JP7592120B2 (ja) 2017-10-22 2023-05-17 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物

Publications (3)

Publication Number Publication Date
JP2021503490A JP2021503490A (ja) 2021-02-12
JP2021503490A5 true JP2021503490A5 (https=) 2021-12-02
JP7282792B2 JP7282792B2 (ja) 2023-05-29

Family

ID=66173073

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543658A Active JP7282792B2 (ja) 2017-10-22 2018-10-22 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物
JP2023081323A Active JP7592120B2 (ja) 2017-10-22 2023-05-17 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023081323A Active JP7592120B2 (ja) 2017-10-22 2023-05-17 前立腺特異的膜抗原発現癌の診断または治療のための新規放射性金属結合化合物

Country Status (8)

Country Link
US (2) US20200339625A1 (https=)
EP (1) EP3700917A4 (https=)
JP (2) JP7282792B2 (https=)
KR (1) KR102884167B1 (https=)
CN (1) CN111630059B (https=)
AU (1) AU2018352731B2 (https=)
CA (1) CA3079906A1 (https=)
WO (1) WO2019075583A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
SG11202005511VA (en) 2017-12-13 2020-07-29 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
WO2020210909A1 (en) * 2019-04-17 2020-10-22 Provincial Health Services Authority Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
CN110317151B (zh) * 2019-06-06 2022-06-24 原子高科股份有限公司 前列腺癌PET诊断试剂68Ga-HBBED-ANCP-PSMA及其制备方法和应用
CN114401947B (zh) * 2019-06-21 2024-11-29 省卫生服务机构 靶向前列腺特异性膜抗原的放射性标记化合物
CA3174082A1 (en) * 2020-03-04 2021-09-10 Nihon Medi-Physics Co., Ltd. Compound and radioactive labeling compound
US20240018110A1 (en) * 2020-12-16 2024-01-18 The University Of British Columbia Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2022167681A1 (en) * 2021-02-08 2022-08-11 Stichting Radboud Universitair Medisch Centrum Psma-targeting ligands for multimodal applications
KR20230154183A (ko) 2021-03-04 2023-11-07 니혼 메디피직스 가부시키가이샤 화합물 및 방사성 표지 화합물
CN113372285B (zh) * 2021-05-28 2024-06-18 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用
CN118852044A (zh) 2021-09-03 2024-10-29 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
CN115806529A (zh) * 2021-09-15 2023-03-17 威智医药有限公司 Psma结合剂及其用途
JP2024544870A (ja) * 2021-11-10 2024-12-05 スージョウ・ルイヘ・メディシン・テクノロジー・カンパニー・リミテッド Psma抗原を標的とするリガンド化合物及びそのキレート並びに前立腺癌の診断及び治療のための応用
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
CN119855612A (zh) * 2022-09-09 2025-04-18 同宜医药(苏州)有限公司 放射性核素偶联药物及其药物组合物和应用
CN116199736B (zh) * 2023-03-01 2025-03-18 西南医科大学附属医院 一种DOTA-Te-PSMA化合物及其应用
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
CN116730983B (zh) * 2023-08-10 2023-11-03 山东大学 一种靶向前列腺特异性抗原的化合物及其制备方法与应用
US20250213705A1 (en) 2023-08-23 2025-07-03 Bright Peak Therapeutics Ag Psma targeting ligands and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
WO2017117687A1 (en) * 2016-01-10 2017-07-13 British Columbia Cancer Agency Branch 18/19f-labelled compounds which target the prostate specific membrane antigen
EP3544960A1 (en) 2016-11-23 2019-10-02 Cancer Targeted Technology LLC Albumin-binding psma inhibitors
US11629201B2 (en) 2017-05-24 2023-04-18 ITM Isotope Technologies Munich SE PSMA-binding agents and uses thereof

Similar Documents

Publication Publication Date Title
JP2021503490A5 (https=)
JP2012511023A5 (https=)
JP2020518674A5 (https=)
JP2023113612A (ja) Psmaを標的としたイメージング及び放射線治療のための金属/放射性金属標識psma阻害剤
EP4473980A3 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
RU2011127468A (ru) Технецкий- и рений-бис(гетероарильные) комплексы и методы их применения для ингибирования psma
JP2010523599A5 (https=)
JP2020520902A5 (https=)
RU2011127467A (ru) Са-ix специфические радиофармпрепараты для лечения и визуализации злокачественных опухолей
JP2010533727A5 (https=)
JP2023179556A5 (https=)
HU208947B (en) Diagnostical compositions and process for producing aminopolycarboxylic acids, their derivatives and metal-kelates
JP2020507589A5 (https=)
JP2022509220A5 (ja) 腫瘍抗原標的化剤、医薬組成物、癌診断薬又は癌治療薬、in vitro法、及びその化合物
AU2017302539B2 (en) Targeted radiotherapy chelates for In Situ Immune Modulated Cancer Vaccination
JP2021502368A (ja) 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法(trt)の使用
JP2016521275A5 (https=)
JP2019535723A5 (https=)
JP2010523477A5 (https=)
CA3119807A1 (en) Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP5856982B2 (ja) 二官能性キレート化剤
JP2020518571A5 (https=)
JP2007505044A5 (https=)
JP2004532820A (ja) 標的放射線療法のためのアクチニウム−225錯体および複合体
JP2010523626A5 (https=)